THIRD AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTEConvertible Note • January 16th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances)
This Third Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of November 13, 2023 (the “Effective Date”) is entered into by and between Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, a “Purchaser” and together, the “Purchasers”).
DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN BENUVIA OPERATIONS, LLC AND CHROMOCELL THERAPEUTICS CORP. DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • January 16th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances) • New York
This Development and License Agreement, made as of December 23, 2023 (the “Effective Date”), is by and between Benuvia Operations, LLC, a Delaware limited liability company, with principal offices located at 3950 N. Mays Street Round Rock, Texas 78665 (“Benuvia”) and Chromocell Therapeutics Corporation, a Delaware corporation, with principal offices located at 685 US-1, North Brunswick Township, NJ 08902 (“Chromocell”). Each of Benuvia and Chromocell may be referred to herein, individually, as a “Party”, and, collectively, as the “Parties”.
Amendment No. 1 to Promissory NoteChromocell Therapeutics Corp • January 16th, 2024 • Biological products, (no disgnostic substances)
Chromocell Therapeutics Corporation, a Delaware corporation (the “Borrower”), and Todd Davis, his successors or assigns (the “Lender”), pursuant to that certain Promissory Note, dated December 6, 2022 (the “Note”), do hereby agree to amend the Note to extend the Maturity Date (as defined in the Note) to February 29, 2024.
STOCK ISSUANCE AGREEMENTStock Issuance Agreement • January 16th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances) • Delaware
This STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of December 23, 2023 (the “Effective Date”) between Chromocell Therapeutics Corporation, a Delaware corporation (“Chromocell”) and Benuvia Operations, LLC, a Delaware limited liability company (“Benuvia”). Chromocell and Benuvia are collectively referred to herein as the “Parties.”
CHROMOCELL THERAPEUTICS CORPORATIONSecurities Purchase Agreement • January 16th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances)
Reference is made to that certain Securities Purchase Agreement, dated as of October 11, 2023 (the “Securities Purchase Agreement”) between Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”), and Dominion Capital LLC, a Connecticut limited liability company (the “Purchaser”), attached hereto as Exhibit A. Capitalized terms used but not defined herein shall have the meanings given to them in the Securities Purchase Agreement.
